Archives

Antonius M. VanDongen, Associate Professor from Duke University, walks us through Arc, a new target for treating Alzheimer’s disease.

Monitoring brain health, particularly cognition, in older adults is increasingly recognised as a significant priority for research, healthcare and broader public health. Find out here about the development and validation of the FLAME System, a computerised cognitive assessment for remote brain health monitoring.

Parkinson’s disease, a progressive neurodegenerative disorder, poses significant challenges for both patients and researchers. In a recent interview with Henri Huttunen from Herantis Pharma Plc, we delved into the intricacies of their potential novel disease-modifying therapy, HER-096.

Effective treatments for amyloid-associated neurological diseases are desperately needed; H. Robert Guy, CEO of Amyloid Research Consultants, talks us through the obstacles and opportunities associated with structure-based drug design.

Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc, charts progress in the development of disease-modifying treatments for Parkinson’s disease.

Bradlee Heckmann, PhD, from USF Health Neuroscience Institute, Byrd Alzheimer’s Center & Asha Therapeutics, in this discussion goes beyond amyloid, asking what’s next for Alzheimer’s Disease therapeutics.

Efforts to prevent or treat Alzheimer’s Disease (AD) by targeting Amyloid beta (Aβ) assemblies should be continued, but the strategies should be altered dramatically.

The WATCH project aims to elucidate how tanycytes mediate physiological processes by acting as gatekeepers between the brain and body, how their dysfunction is involved in various disorders and age-related impairments, and what can be done to prevent or correct these.

Further understanding of the characteristics of the responders may shed light on how B vitamins benefit brain health and the formulation of more effective forms of B vitamins.

Henry Scowcroft from Alzheimer’s Research UK, argues that an Alzheimer’s drug, lecanemab, can slow memory decline in a phase 3 trial.